JP2021534217A5 - - Google Patents
Info
- Publication number
- JP2021534217A5 JP2021534217A5 JP2021510070A JP2021510070A JP2021534217A5 JP 2021534217 A5 JP2021534217 A5 JP 2021534217A5 JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021510070 A JP2021510070 A JP 2021510070A JP 2021534217 A5 JP2021534217 A5 JP 2021534217A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- improvement
- reduction
- individual
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720671P | 2018-08-21 | 2018-08-21 | |
| US62/720,671 | 2018-08-21 | ||
| PCT/US2019/047305 WO2020041340A1 (en) | 2018-08-21 | 2019-08-20 | The use of alpha-2-adrenergic receptor agonists for improving vision |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534217A JP2021534217A (ja) | 2021-12-09 |
| JPWO2020041340A5 JPWO2020041340A5 (https=) | 2022-08-26 |
| JP2021534217A5 true JP2021534217A5 (https=) | 2022-08-26 |
Family
ID=67841225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510070A Pending JP2021534217A (ja) | 2018-08-21 | 2019-08-20 | 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20210205273A1 (https=) |
| EP (1) | EP3840750A1 (https=) |
| JP (1) | JP2021534217A (https=) |
| KR (1) | KR20210047323A (https=) |
| CN (1) | CN112823003A (https=) |
| AR (1) | AR115991A1 (https=) |
| AU (1) | AU2019325486A1 (https=) |
| BR (1) | BR112021003295A2 (https=) |
| CA (1) | CA3110318A1 (https=) |
| CL (1) | CL2021000440A1 (https=) |
| CO (1) | CO2021003460A2 (https=) |
| IL (1) | IL280990A (https=) |
| MX (1) | MX2021002112A (https=) |
| PH (1) | PH12021550372A1 (https=) |
| SG (1) | SG11202101730SA (https=) |
| TW (1) | TW202021584A (https=) |
| WO (1) | WO2020041340A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023514732A (ja) * | 2020-02-20 | 2023-04-07 | アラーガン、インコーポレイテッド | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
| US12023276B2 (en) | 2021-02-24 | 2024-07-02 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
| AU2024217271A1 (en) * | 2023-02-08 | 2025-09-18 | Bausch + Lomb Ireland Limited | Alpha-2-adrenergic agonists for improving vision |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| EP3085358B1 (en) | 2010-01-22 | 2017-11-01 | Allergan, Inc. | Intracameral sustained release therapeutic agent implants |
| WO2012149381A1 (en) * | 2011-04-28 | 2012-11-01 | Alpha Synergy Development, Inc. | Compositions and methods for improving night vision |
| US10507245B2 (en) * | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| WO2014143754A2 (en) | 2013-03-15 | 2014-09-18 | Allergan, Inc. | Prostamide-containing intraocular implant |
| JP2016515583A (ja) | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク．ＦｏｒＳｉｇｈｔ ＶＩＳＩＯＮ５， Ｉｎｃ． | オキュラー・インサートおよびその使用方法 |
| ES2834964T3 (es) | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| CN103338483B (zh) * | 2013-07-24 | 2016-08-10 | 成都西加云杉科技有限公司 | 数据分流方法、数据分流设备及异构网络 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US20160296532A1 (en) | 2015-04-13 | 2016-10-13 | Forsight Vision5, Inc. | Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent |
| US11077053B2 (en) * | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
-
2019
- 2019-08-20 AU AU2019325486A patent/AU2019325486A1/en not_active Abandoned
- 2019-08-20 WO PCT/US2019/047305 patent/WO2020041340A1/en not_active Ceased
- 2019-08-20 TW TW108129699A patent/TW202021584A/zh unknown
- 2019-08-20 CN CN201980065608.3A patent/CN112823003A/zh active Pending
- 2019-08-20 KR KR1020217008132A patent/KR20210047323A/ko not_active Withdrawn
- 2019-08-20 MX MX2021002112A patent/MX2021002112A/es unknown
- 2019-08-20 JP JP2021510070A patent/JP2021534217A/ja active Pending
- 2019-08-20 US US17/055,922 patent/US20210205273A1/en not_active Abandoned
- 2019-08-20 EP EP19762588.2A patent/EP3840750A1/en not_active Withdrawn
- 2019-08-20 BR BR112021003295-9A patent/BR112021003295A2/pt not_active IP Right Cessation
- 2019-08-20 SG SG11202101730SA patent/SG11202101730SA/en unknown
- 2019-08-20 CA CA3110318A patent/CA3110318A1/en active Pending
- 2019-08-21 AR ARP190102374A patent/AR115991A1/es not_active Application Discontinuation
-
2021
- 2021-02-21 IL IL280990A patent/IL280990A/en unknown
- 2021-02-22 CL CL2021000440A patent/CL2021000440A1/es unknown
- 2021-02-22 PH PH12021550372A patent/PH12021550372A1/en unknown
- 2021-03-17 CO CONC2021/0003460A patent/CO2021003460A2/es unknown
- 2021-06-30 US US17/364,470 patent/US20220160623A1/en not_active Abandoned
- 2021-10-29 US US17/452,963 patent/US20220288031A1/en not_active Abandoned
-
2024
- 2024-03-08 US US18/599,800 patent/US20240358682A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI361701B (en) | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye | |
| JP2023105147A5 (https=) | ||
| JP2019524826A5 (https=) | ||
| JP2017061467A5 (https=) | ||
| EP1328186A1 (en) | Methods for treating various eye disorders | |
| WO2017204298A1 (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP2021534217A5 (https=) | ||
| CN114585365A (zh) | 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点 | |
| WO2019191525A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| JP2005501100A (ja) | 視力を改善する生理学的方法 | |
| US6730691B1 (en) | Uses of alpha adrenergic blocking agents | |
| Nagpal et al. | Spontaneous regression (autoinfarction) of proliferative sickle retinopathy | |
| CN110114066B (zh) | 含沙丁胺醇的眼科药物 | |
| Choi et al. | Goniotomy for steroid-induced glaucoma: clinical and tonographic evidence to support therapeutic goniotomy | |
| JP6267003B2 (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| Ruparelia et al. | Multiple XEN gel stents for refractory pediatric glaucoma | |
| WO2012111029A2 (en) | Ophthalmic composition for enabling dilation of pupils | |
| JPWO2020041340A5 (https=) | ||
| Pérez-Sarriegui et al. | Phaco-non-penetrating deep sclerectomy in ocular hypertension secondary to dexamethasone intravitreal implant | |
| de Klerk et al. | I-Stent for treatment of angle recession with raised intraocular pressure. | |
| JPWO2021168349A5 (https=) | ||
| US20260083730A1 (en) | Methods of treating eye disorders | |
| RU2021106014A (ru) | Применение агонистов альфа-2-адренергических рецепторов для улучшения зрения | |
| Hill et al. | Year in review of optometric advancements | |
| WO2025005896A1 (en) | Ophthalmic viscoelastic formulations suitable for use in cataract surgery |